Supplementary Methods. Supplementary Tables S1-7. Supplementary Figures S1 and S2 from Assessment of EGFR Mutation Status in Matched Plasma and Tumor Tissue of NSCLC Patients from a Phase I Study of Rociletinib (CO-1686)

Autor: Heather Wakelee, Keunchil Park, Andrew R. Allen, Mitch Raponi, Lindsey Rolfe, Darrin Despain, Shannon Matheny, Patrick O'Donnell, Sean Chien, Lin Wu, Cloud Paweletz, Shirish Gadgeel, D. Ross Camidge, Benjamin Solomon, Jean-Charles Soria, David Spigel, Leora Horn, Philipp Angenendt, Wei Wen, Krzysztof Konopa, Lecia V. Sequist, Elaina Mann, Jong-Mu Sun, Jonathan W. Goldman, Chris Karlovich
Rok vydání: 2023
Popis: Supplementary Tables S1-7. Supplementary Table S1. Clinical characteristics of patients in the present analysis. Supplementary Table S2. Plasma/tissue concordance results for del19 and L858R mutations. Supplementary Table S3. EGFR mutations identified in tissue and plasma by the cobas® EGFR mutation test. Supplementary Table S4. Concordance between tumor and BEAMing plasma EGFR status. Supplementary Table S5. Overall concordance between cobas® and BEAMing EGFR mutation tests. Supplementary Table S6. Platform Comparison of T790M tests in a sample set enriched for low copy plasma cases. Supplementary Table S7. EGFR mutation detection by cobas® plasma test and NSCLC disease classification (n = 72) Supplementary Figures S1-2. Supplementary Figure S1. Tumor burden is a weak predictor of ability to detect EGFR mutations in plasma. Supplementary Figure S2. T790M to activating mutation ratio in plasma is associated with depth of response to rociletinib.
Databáze: OpenAIRE